T1	Participants 83 144	rheumatoid arthritis patients who had no clinical improvement
T2	Participants 186 267	anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy
T3	Participants 321 440	inflammation and joint destruction in rheumatoid arthritis (RA) patients who have not responded clinically to treatment
